Patents by Inventor Barbara A. Chicca

Barbara A. Chicca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7348406
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: March 25, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka
  • Patent number: 7326678
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: February 5, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Mary Ruth Erickson, Barbara A. Chicca, Bernard Bihain, Hiroaki Tanaka, Tom Chu, Deno P. Dialynas, Aaron Scalia
  • Publication number: 20040235709
    Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP3 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
    Type: Application
    Filed: March 8, 2004
    Publication date: November 25, 2004
    Inventors: Luisa Salter-Cid, Dana Ebbets-Reed, Barbara A. Chicca, John Chicca, Frances Yen-Potin, Bernard Bihain